Novo Nordisk's New Obesity Drug CagriSema Outperforms Rival Treatment

The news indicates that Novo Nordisk's new obesity drug CagriSema has outperformed a rival treatment; this is a positive clinical/commercial development. However, the stock has fallen 6.7% in the last 24 hours and the RSI is at 21, in oversold territory, with MACD negative and the price below the SMA20/50. In the short term, there may be a relief rally due to the news, but the strong downtrend and weak technical picture could limit upward movement. Therefore, I expect a slightly positive trend for 1-3 days, but confidence is low.

The news that Novo Nordisk's CagriSema outperformed a rival treatment could create competitive pressure on LLY and pose downside risk to the stock in the short term. Technical indicators point to overbought territory: RSI14 at 70.6, above the critical level, and the price significantly above the SMA20 and SMA50. This, combined with negative news flow, could trigger profit-taking. However, MACD is positive and above the signal line, indicating the trend is still strong; therefore, the bearish signal is moderately reliable. In the short term, the 1147 (SMA20) level can be monitored as the first support.